

# Imaging of the Human Brain in Health and Disease

Edited by:

Philip Seeman

Bertha Madras



Book 1 in the Neuroscience-Net Reference Book Series

John E. Johnson, Jr., Managing Editor





# IMAGING OF THE HUMAN BRAIN IN HEALTH AND DISEASE

Edited by

PHILIP SEEMAN, SETHA MADRAS



ELSEVIER

Amsterdam • Boston • Heidelberg • London  
New York • Oxford • Paris • San Diego  
San Francisco • Sydney • Tokyo

Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier  
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK  
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands  
225 Wyman Street, Waltham, MA 02451, USA  
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

First edition 2014

© 2014 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [permissions@elsevier.com](mailto:permissions@elsevier.com). Alternatively you can submit your request online by visiting the Elsevier web site at <http://elsevier.com/locate/permissions>, and selecting Obtaining permission to use Elsevier material.

#### Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

#### Library of Congress Cataloging-in-Publication Data

Imaging of the human brain in health and disease / edited by Philip Seeman, Bertha Madras. – 1st edition.

p. ; cm.

Includes bibliographical references and index.

Summary: "Modern imaging techniques have allowed researchers to non-invasively peer into the human brain and investigate, among many other things, the acute effects and long-term consequences of drug abuse. Here, we review the most commonly used and some emerging imaging techniques in addiction research, explain how the various techniques generate their characteristic images and describe the rationale that researchers use to interpret them. In addition, examples of seminal imaging findings are highlighted that illustrate the contribution of each imaging modality to the expansion in our understanding of the neurobiological bases of drug abuse and addiction, and how they can be parlayed in the future into clinical and therapeutic applications"— Provided by publisher.

ISBN 978-0-12-418677-4 (alk. paper)

I. Seeman, Philip, editor of compilation. II. Madras, Bertha, editor of compilation.

[DNLM: 1. Neuroimaging--methods. 2. Brain Chemistry--physiology. 3. Brain Diseases--radionuclide imaging. 4. Mental Disorders--radionuclide imaging. 5. Substance-Related Disorders--radionuclide imaging.

WL 141.5.N47]

RC386.6.T65

616.8'047575--dc23

2013039184

#### British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

For information on all Academic Press publications  
visit our web site at [store.elsevier.com](http://store.elsevier.com)

Printed and bound in USA

14 15 16 17 18 10 9 8 7 6 5 4 3 2 1

ISBN: 978-0-12-418677-4



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)



# **IMAGING OF THE HUMAN BRAIN IN HEALTH AND DISEASE**

# LIST OF CONTRIBUTORS

**Ruben Baler**

National Institute on Drug Abuse, Bethesda, MD, USA

**James Robert Brašić**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Section of High Resolution Brain Positron Emission Tomography Imaging, Division of Nuclear Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

**Guy Bormans**

MoSAIC, Molecular Small Animal Imaging Center, KU Leuven, Leuven, Belgium; Laboratory for Radiopharmacy, KU Leuven, Leuven, Belgium

**Cindy Casteels**

Division of Nuclear Medicine, University Hospitals and KU Leuven, Leuven, Belgium; MoSAIC, Molecular Small Animal Imaging Center, KU Leuven, Leuven, Belgium

**Sofia N. Chatziioannou**

Department of Radiology, Nuclear Medicine Section, National and Kapodistrian University of Athens Medical School, Attikon General Hospital, Athens, Greece

**Thilo Deckersbach**

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

**Lora Deutch**

Departments of Radiology, University of Pittsburgh, Pittsburgh, PA, USA

**Darin D. Dougherty**

Department of Psychiatry, Massachusetts General Hospital, Charlestown, MA, USA

**Andre C. Felicio**

Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada

**Joanna S. Fowler**

Brookhaven National Laboratory, Upton, NY, USA

**Boris Frolov**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Hironobu Fujiwara**

Molecular Imaging Center, Department of Molecular Neuroimaging, National Institute of Radiological Sciences, Inage, Chiba, Japan

**Camille Garcia-Ramos**

Department of Medical Physics, University of Wisconsin–Madison, WI, USA

**Emily Gean**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Noble George**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Sharmin Ghaznavi**

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

**Udi E. Ghitza**

Center for the Clinical Trials Network, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA

**Roger N. Gunn**

Imanova Limited, London, UK; Department of Medicine, Imperial College, London, UK; Department of Engineering Science, University of Oxford, UK

**Christer Halldin**

Department of Clinical Neuroscience, Karolinska Institutet, Centre for Psychiatry Research, Stockholm, Sweden

**Jarmo Hietala**

Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland; Department of Psychiatry, University of Turku, Turku, Finland

**Jussi Hirvonen**

Department of Radiology, Turku University Hospital and University of Turku, Turku, Finland; Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland

**Andrew Horti**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Kiichi Ishiwata**

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

**Karin B. Jensen**

Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

**Robert M. Kessler**

Department of Radiology and Radiological Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA

**Yuichi Kimura**

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan

**Christian La**

Department of Radiology, University of Wisconsin–Madison, WI, USA; Department of Medical Physics, University of Wisconsin–Madison, WI, USA; Neuroscience Training Program, University of Wisconsin–Madison, WI, USA

**Koen Van Laere**

Division of Nuclear Medicine, University Hospitals and KU Leuven, Leuven, Belgium;  
MoSAIC, Molecular Small Animal Imaging Center, KU Leuven, Leuven, Belgium

**Marco L. Loggia**

Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital,  
Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General  
Hospital, Harvard Medical School, Boston, MA, USA

**Masahiro Mishina**

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; The  
Second Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

**Mona Mohamed**

Division of Neuroradiology, The Russell H. Morgan Department of Radiology and  
Radiological Science, The Johns Hopkins University School of Medicine, Baltimore,  
Maryland, USA

**Ayon Nandi**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins  
University School of Medicine, Baltimore, MD, USA

**Veena A. Nair**

Department of Radiology, University of Wisconsin–Madison, WI, USA

**Rajesh Narendran**

Departments of Radiology, University of Pittsburgh, Pittsburgh, PA, USA; Department of  
Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA

**Yoshiro Okubo**

Department of Neuropsychiatry, Nippon Medical School, Bunkyo-ku, Tokyo, Japan

**Vivek Prabhakaran**

Department of Radiology, University of Wisconsin–Madison, WI, USA; Neuroscience Training  
Program, University of Wisconsin–Madison, WI, USA; Department of Neurology, University  
of Wisconsin–Madison, WI, USA; Department of Psychiatry, University of Wisconsin–Madison,  
WI, USA; Medical Scientist Training Program, University of Wisconsin–Madison, WI, USA

**Eugenii A. Rabiner**

Imanova Limited, London, UK; Institute of Psychiatry, Kings College, London, UK

**Emmanouil N. Rizos**

Department of Psychiatry, National and Kapodistrian University of Athens Medical School,  
Attikon General Hospital, Athens, Greece

**Muneyuki Sakata**

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

**Hitoshi Shimada**

Molecular Imaging Center, Department of Molecular Neuroimaging, National Institute of  
Radiological Sciences, Inage, Chiba, Japan

**Mark Slifstein**

Department of Psychiatry, Columbia University, New York, NY, USA; Division of Translational  
Imaging, New York State Psychiatric Institute, New York, NY, USA

**A. Jon Stoessl**

Pacific Parkinson's Research Centre, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada

**Tetsuya Suhara**

Molecular Imaging Center, Department of Molecular Neuroimaging, National Institute of Radiological Sciences, Inage, Chiba, Japan

**Hidehiko Takahashi**

Molecular Imaging Center, Department of Molecular Neuroimaging, National Institute of Radiological Sciences, Inage, Chiba, Japan; Department of Psychiatry, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan

**Dardo Tomasi**

National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

**Jun Toyohara**

Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan

**Andrea Varrone**

Department of Clinical Neuroscience, Karolinska Institutet, Centre for Psychiatry Research, Stockholm, Sweden

**Nora D. Volkow**

National Institute on Drug Abuse, Bethesda, MD, USA

**Gene-Jack Wang**

Brookhaven National Laboratory, Upton, NY, USA

**Dean F. Wong**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Environmental Health Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Carey School of Business, Johns Hopkins University School of Medicine, Baltimore, MD, USA

**Brittany M. Young**

Department of Radiology, University of Wisconsin–Madison, WI, USA; Neuroscience Training Program, University of Wisconsin–Madison, WI, USA; Medical Scientist Training Program, University of Wisconsin–Madison, WI, USA

**Eram Zaidi**

The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA



# CONTENTS

*List of Contributors*

*xi*

<b>1. Neuroimaging of Addiction</b>	<b>1</b>
Nora D. Volkow, Gene-Jack Wang, Joanna S. Fowler, Dardo Tomasi and Ruben Baler	
1. Introduction	1
2.1. Magnetic resonance-based imaging techniques	1
2.2. Nuclear medicine imaging techniques	10
2.3. Clinical applications of imaging	16
3. Conclusions	20
Acknowledgments	20
References	20
<b>2. Brain PET Imaging in the Cannabinoid System</b>	<b>27</b>
Dean F. Wong, Ayon Nandi, Eram Zaidi, Emily Gean, Andrew Horti, Boris Frolov, Noble George and James R. Brasic	
1. Introduction	27
2.1. First attempts at imaging CB1R with pet: a historical perspective	28
2.2. The currently available pet radioligands	29
2.3. Applications of cannabinoid imaging	32
3. Conclusions	33
References	34
<b>3. Brain Imaging of Cannabinoid Receptors</b>	<b>37</b>
Cindy Casteels, Guy Bormans and Koen Van Laere	
1. Introduction	37
1.2. ECS in brain pathology	41
2.1. Molecular imaging of the ECS	45
2.2. Imaging of cannabinoid receptors	49
3. Conclusions	68
References	68
<b>4. Human Brain Imaging of Opioid Receptors: Application to CNS Biomarker and Drug Development</b>	<b>81</b>
Udi E. Ghitza	
1. Introduction	81
2.1. CNS opioid receptors	83

2.2. OR-radiolabeled tracers	84
2.3. PET imaging of $\mu$ -OR	85
2.4. PET imaging of $\delta$ -OR and $\kappa$ -OR	86
2.5. PET imaging studies of the $\mu$ -OR and drug use	87
2.6. Characterizing actions of putative OR-acting analgesics: combined molecular imaging of occupancy of $\mu$ -OR in tandem with reward-related or pain-related functional brain activation in humans	92
3. Conclusions	93
Acknowledgments	96
References	96
<b>5. Brain Imaging of Sigma Receptors</b>	<b>99</b>
Muneyuki Sakata, Jun Toyohara and Kiichi Ishiwata	
1. Introduction	99
2.1. Postmortem studies	100
2.2. Radioligands for imaging sigma receptors	102
2.3. Human PET imaging of the sigma <sub>1</sub> receptor	104
3. Conclusions	108
Abbreviations	109
References	109
<b>6. Human Brain Imaging of Acetylcholine Receptors</b>	<b>113</b>
Jun Toyohara, Muneyuki Sakata and Kiichi Ishiwata	
1. Introduction	113
2.1. Postmortem studies	117
2.2. Radioligands for imaging AChRs	118
2.3. Human SPECT/PET imaging of mAChR	125
2.4. Human SPECT/PET imaging of mAChR in the diseased brain	131
2.5. Human SPECT/PET imaging of $\alpha 4\beta 2$ nAChR	136
2.6. Human SPECT/PET imaging of $\alpha 7$ nAChR	143
3. Conclusions	145
Abbreviations	145
References	147
<b>7. Human Brain Imaging of Adenosine Receptors</b>	<b>161</b>
Masahiro Mishina, Yuichi Kimura and Kiichi Ishiwata	
1. Introduction	161
2.1. Postmortem studies	163
2.2. Imaging of A <sub>1</sub> and A <sub>2A</sub> receptors	164
2.3. Quantification of adenosine receptors	170

3. Conclusions	180
Abbreviations	180
References	181
<b>8. Human Brain Imaging of Dopamine D<sub>1</sub> Receptors</b>	<b>187</b>
Hironobu Fujiwara, Hidehiko Takahashi, Hitoshi Shimada, Yoshiro Okubo and Tetsuya Suhara	
1. Introduction	187
2.1. Affective and cognitive functions and D <sub>1</sub> receptors in humans	188
2.2. D <sub>1</sub> receptor and psychiatric disorders	197
3. Conclusions	199
References	200
<b>9. Human Brain Imaging of Dopamine Transporters</b>	<b>203</b>
Andrea Varrone and Christer Halldin	
1. Introduction	203
2.1. In vivo imaging of the DAT - Part I	210
2.2. In vivo imaging of the DAT - Part II	216
2.3. In vivo imaging of the DAT - Part III	220
3. Conclusions	227
References	238
<b>10. Imaging of Dopamine and Serotonin Receptors and Transporters</b>	<b>241</b>
Andre C. Felicio and A. Jon Stoessl	
1. Introduction	241
2.1. Parkinson's disease as a model for understanding molecular imaging	242
2.2. Tracers for the assessment of presynaptic dopamine function	244
2.3. Transporters	245
2.4. Tracers for the assessment of postsynaptic dopamine function	248
2.5. Other tracers: serotonergic binding ligands	249
2.6. Clinical relevance	250
3. Conclusions	257
Acknowledgments	257
References	258
<b>11. Imaging the Dopamine D<sub>3</sub> Receptor In Vivo</b>	<b>265</b>
Mark Slifstein, Eugenii A. Rabiner and Roger N. Gunn	
1. Introduction	265
2.1. PET imaging with [ <sup>11</sup> C]-(+)-phno	267

2.2. D <sub>3</sub> receptor imaging in neuropsychiatric illness	275
3. Conclusions	281
References	282
<b>12. Dopamine Receptors and Dopamine Release</b>	<b>289</b>
Robert M. Kessler	
1. Introduction	289
2.1. Dopamine D <sub>1</sub> family receptors	289
2.2. Clinical studies of the dopamine D <sub>1</sub> receptor	293
2.3. Dopamine D <sub>2</sub> family receptors	295
2.4. Effects of extracellular DA levels on dopamine D <sub>2/3</sub> receptor binding	307
2.5. Clinical studies using dopamine D <sub>2</sub> type receptor ligands	315
3. Conclusions	322
References	323
<b>13. Dopamine Receptor Imaging in Schizophrenia: Focus on Genetic Vulnerability</b>	<b>341</b>
Jussi Hirvonen and Jarmo Hietala	
1. Introduction	341
2.1. Overview of molecular imaging techniques	342
2.2. Dopamine D <sub>2</sub> receptor imaging in schizophrenia	344
2.3. Dopamine D <sub>1</sub> receptor imaging in schizophrenia	349
2.4. Summary: the dopamine hypothesis of schizophrenia vulnerability	351
3. Conclusions	353
References	354
<b>14. Human Brain Imaging in Tardive Dyskinesia</b>	<b>361</b>
Sofia N. Chatziioannou and Emmanouil N. Rizos	
1. Introduction	361
2.1. Nuclear medicine modalities	362
2.2. Magnetic resonance imaging	366
2.3. Computed tomography	368
3. Conclusions	368
References	368
<b>15. Human Brain Imaging of Autism Spectrum Disorders</b>	<b>373</b>
James Robert Brašić and Mona Mohamed	
1. Introduction	373
2.1. Structural human brain imaging of autism spectrum disorders	376
2.2. Functional human brain imaging of autism spectrum disorders	377
3. Conclusions	388

Acknowledgments	396
References	396
<b>16. Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease</b>	<b>407</b>
Noble George, Emily Gean, Ayon Nandi, James Robert Brašić and Dean F. Wong	
1. Introduction	407
2.1. Overview	408
2.2. Amyloid plaques	409
2.3. Tau imaging agents	414
3. Conclusions	415
References	415
<b>17. Human Brain Imaging of Anger</b>	<b>417</b>
Sharmin Ghaznavi, Thilo Deckersbach and Darin D. Dougherty	
1. Introduction	417
2.1. Angered: neuroimaging of the subjective experience of anger	417
2.2. Angry faces, bodies, and voices: neuroimaging of the perception of anger	419
2.3. From anger to aggression to violence	422
3. Conclusions	423
References	424
<b>18. Imaging Pain in the Human Brain</b>	<b>427</b>
Marco L. Loggia and Karin B. Jensen	
1. Introduction	427
2.1. Pain processing in the brain	429
2.2. The descending pain modulatory pathway	432
2.3. Psychological modulation of pain	433
2.4. Chronic pain	436
3. Conclusions	443
Acknowledgments	443
References	443
<b>19. Imaging of Neurochemical Transmission in the Central Nervous System</b>	<b>453</b>
Lora Deutch and Rajesh Narendran	
1. Introduction	453
2.1. Imaging of da transmission	454
2.2. Imaging of serotonin transmission	472
2.3. Imaging of gamma-aminobutyric acid transmission	474
2.4. Imaging of glutamate transmission	474
2.5. Imaging of opioid transmission	475

3. Conclusions	476
References	476
<b>20. Characterizing Recovery of the Human Brain following Stroke: Evidence from fMRI Studies</b>	<b>485</b>
Christian La, Brittany M. Young, Camille Garcia-Ramos, Veena A. Nair and Vivek Prabhakaran	
1. Introduction	485
2.1. fMRI and stroke	486
3. Conclusions	501
Acknowledgments	501
References	501
<b>Index</b>	<b>507</b>

# Neuroimaging of Addiction

Nora D. Volkow<sup>1</sup>, Gene-Jack Wang<sup>2</sup>, Joanna S. Fowler<sup>2</sup>, Dardo Tomasi<sup>3</sup>  
and Ruben Baler<sup>1</sup>

<sup>1</sup>National Institute on Drug Abuse, Bethesda, MD, USA

<sup>2</sup>Brookhaven National Laboratory, Upton, NY, USA

<sup>3</sup>National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA

## 1. INTRODUCTION

Scientific advances over the past 20 to 30 years have established drug addiction as a chronic brain disease (Leshner, 1997). Key evidence supporting this concept was produced by brain imaging studies of drug abusers obtained during or following various periods of drug exposure. These studies have provided information on drugs' neurobiological effects, helped explain the causes and mechanisms of vulnerability to drug abuse, and yielded important insights into abusers' subjective experiences and behaviors, including their difficulty to attain a sustained, relapse-free recovery. Clinicians may be able, in the not too distant future, to use brain imaging to evaluate the level and pattern of brain dysfunction in their addicted patients, helping them to tailor their treatments and to monitor their response to therapy.

The seven primary brain imaging techniques – structural magnetic resonance imaging (MRI), functional MRI, resting functional MRI, Diffusion Tensor Imaging (DTI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), and single photon emission computed tomography (SPECT) – reveal different aspects of brain structure and/or function (Bandettini, 2009; Detre and Floyd, 2001; Duyn and Koretsky, 2011; Johansen-Berg and Rushworth, 2009; Sharma and Ebadi, 2008). Individually, the techniques yield highly complementary information about brain anatomy and tissue composition; biochemical, physiological, and functional processes; neurotransmitter levels; energy utilization and blood flow; and drug distribution and kinetics. Together, and in combination with other research techniques they contribute to continuously improve our understanding of drug abuse and addiction.

## 2.1. MAGNETIC RESONANCE-BASED IMAGING TECHNIQUES

### 2.1.1. Structural Magnetic Resonance Imaging

Structural magnetic resonance imaging (sMRI) translates the local differences in water content into different shades of gray that serve to outline the shapes and sizes of the

brain's various subregions. An MRI scanner delivers a specific radiofrequency that excites hydrogen atoms in the water molecule, which return some of this energy in the form of a characteristic nuclear magnetic resonance signal. Not all protons "resonate" in that way, but enough do such that the resulting computer-generated image constitutes a highly detailed map of the brain's tissues and structures. Thus, this tool can be used to discover the presence of abnormal tissue through the changes in tissue density or composition. Scientists examining an sMRI can readily distinguish between gray and white matter and other types of tissue—both normal, such as blood vessels, and abnormal, such as tumors—by their different shading and contrast with surrounding areas.

Such measurements can help scientists and doctors to home in on the regions that are most heavily affected by drugs. Importantly, these initial observations often guide additional investigations, using other research tools and techniques, to determine the reasons for the structural changes as well as their experiential and behavioral consequences. As explained below, sMRI studies have provided detailed evidence that chronic drug exposure can lead to both increases and reductions in the volume of specific brain regions.

## **Drug Exposure can Trigger Abnormalities in Prefrontal Cortex and Other Brain Regions**


Numerous sMRI studies have documented that addictive drugs can cause volume and tissue composition changes in the prefrontal cortex (PFC), a brain region that supports logical thinking, goal-directed behaviors, planning, and self-control. These changes in turn are likely to be associated with drug abusers' cognitive and decision-making deficiencies. Related to this finding, another sMRI study found that individuals with a history of abusing multiple substances have smaller prefrontal lobes than did matched controls (Liu et al., 1998).

These findings add to the growing evidence associating prefrontal abnormalities with the abuse of various substances (Goldstein and Volkow, 2002; Stapleton et al., 1995; Volkow et al., 1991). For example, using sMRI, Schlaepfer and colleagues found that chronic substance abusers' frontal lobe tissues contained a lower proportion of white matter than those of matched controls did (Schlaepfer et al, 2006). Interestingly, similar deficits in white matter content have been found in individuals with other psychiatric disorders that tend to cooccur with substance abuse.

Pertaining to the abuse of stimulants, Kim and colleagues (Kim et al., 2006) documented a reduction in the gray-matter density in the right middle frontal cortex of abstinent methamphetamine abusers (Figure 1). A lower density correlated with a worse performance on a test that measures a person's ability to switch mental gears (Wisconsin Card Sorting Task). Gray matter was closer to normal in individuals who had been abstinent for >6 months than in others with a shorter period of abstinence.

In another sMRI study, cocaine abusers who had been abstinent for 20 days exhibited a reduced gray-matter density in the regions of the frontal cortex. Interestingly, no





**Figure 1** MRI: methamphetamine reduces gray matter. The yellow and red area in the central brain view indicates a reduced gray-matter density in the right middle frontal cortex. The same deficit is shown from other perspectives in the flanking views. *Reprinted with permission from Kim et al. (2006).*